Newsroom | 50185 results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL. Together with its collaborators, Natera will demonstrate unmatched scale in evidence generation with 35 abstracts across molecular residual disease (MRD) testing and other innovations. Presentations w...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, a clinical-stage immuno-oncology company developing an immune-activating antibody therapeutic designed by leveraging an AI platform, today announced positive Phase 2 data from its ongoing Phase 1/2 study of imneskibart in patients with doublet checkpoint inhibitor (CPI)-refractory metastatic melanoma. The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago, Illinois. Th...

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia will present two posters highlighting how its tests provide insights into treatment response and aid therapeutic decision-making for EBC....

PRINCETON, N.J.--(BUSINESS WIRE)--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 - June 2, 2026, in Chicago, Illinois. Flatiron's high-quality real-world data and innovative research capabilities are featured across 25+ research acceptances, including 14 Flatiron-authored poster presentations and online publications. Flatiron’s presence at ASCO 2026 closely follows the launch of Flatiron Telescope, a multi-agent ada...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago. “The presentations at ASCO this year highlight the continued progress of our strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the d...

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, will present new findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where the cancer center will showcase 49 abstracts spanning solid tumors and blood cancers. This year’s research, to be prese...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago. Two breast cancer abstracts demonstrate the performance of Artera’s MMAI across clinically challenging settings. One study assesses prognosis and chemotherapy benefit stratification in node‑positive HR+ breast cancer...

CHICAGO--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for solid tumors, today announced the presentation of safety and efficacy data from the ongoing EVEREST-2 clinical study (NCT06051695). The findings, which are being presented in poster presentations during the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 29 – June 2, 2026, in Chicago, include updates on t...